Bastian Hengerer

Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors.

The mRNAs of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) exhibit a similar, though not identical, regional and cellular distribution in the rodent brain. In situ hybridization experiments have shown that BDNF, like NGF, is predominantly expressed by neurons. The neuronal localization of the mRNAs of these two neurotrophic molecules raised the question as to whether neuronal activity might be involved in the regulation of their synthesis. After we had demonstrated that depolarization with high potassium (50 mM) resulted in an increase in the levels of both BDNF and NGF mRNAs in cultures of hippocampal neurons, we investigated the effect of a large number of transmitter substances. Kainic acid, a glutamate receptor agonist, was by far the most effective in increasing BDNF and NGF mRNA levels in the neurons, but neither N‐methyl‐D‐aspartic acid (NMDA) nor inhibitors of the NMDA glutamate receptors had any effect. However, the kainic acid mediated increase was blocked by antagonists of non‐NMDA receptors. Kainic acid also elevated levels of BDNF and NGF mRNAs in rat hippocampus and cortex in vivo. These results suggest that the synthesis of these two neurotrophic factors in the brain is regulated by neuronal activity via non‐NMDA glutamate receptors.

Genetic ablation of tumor necrosis factor alpha (TNF-alpha) and pharmacological inhibition of TNF synthesis attenuates MPTP toxicity in mouse striatum

The impact of pro‐inflammatory cytokines such as tumor necrosis factor‐α (TNF‐α) in the pathology of Parkinsons disease (PD) and in MPTP neurotoxicity remains unclear. Here, male TNF‐α (–/–) deficient mice and C57bL/6 mice were treated with MPTP (4 × 15mg/kg, 24 h intervals) and in one series, thalidomide was administered to inhibit TNF‐α synthesis. Real‐time RT‐PCR revealed that the striatal mRNA levels of TNF‐α, of the astrocytic marker glial fibrillary acidic protein (GFAP) and of the marker for activated microglia, macrophage antigen complex‐1 (MAC‐1), were significantly enhanced after MPTP administration. Thalidomide (50 mg/kg, p.o.) partly protected against the MPTP‐induced dopamine (DA) depletion, and TNF‐α (–/–) mice showed a significant attenuation of striatal DA and DA metabolite loss as well as striatal tyrosine hydroxylase (TH) fiber density, but no difference in nigral TH and DA transporter immunoreactivity. TNF‐α deficient mice suffered a lower mortality (10%) compared to the high mortality (75%) seen in wild‐type mice after acute MPTP treatment (4 × 20mg/kg, 2 h interval). HPLC measurement of MPP+ levels revealed no differences in TNF‐α (–/–), wild‐type and thalidomide treated mice. This study demonstrates that TNF‐α is involved in MPTP toxicity and that inhibition of TNF‐α response may be a promising target for extending beyond symptomatic treatment and developing anti‐parkinsonian drugs for the treatment of the inflammatory processes in PD.

Transforming growth factor-β1 stimulates expression of nerve growth factor in the rat CNS

Transforming growth factor-beta 1 (TGF-beta 1) markedly increased the mRNA encoding nerve growth factor (NGF) in cultured rat astrocytes in a time- and concentration-dependent manner. The maximal effect of TGF-beta 1 (a 50-fold increase in NGF-mRNA) was reached after 24 h incubation. The TGF-beta-mediated increase in NGF-mRNA results from enhanced transcription as shown in nuclear run-on studies and in transfection assays using the NGF promoter linked to a chloramphenicol acetyltransferase (CAT) reporter gene. TGF-beta 1 also increased its own expression in astrocytes as well as that of the proto-oncogene c-fos. Intraventricular injection of TGF-beta 1 resulted in an increase of NGF-mRNA levels in the rat hippocampus (3-4 fold) showing that TGF-beta 1 is also effective in increasing NGF expression in vivo.

Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells.

Nurr1, a transcription factor belonging to the nuclear receptor family, is essential for the generation of midbrain dopamine (DA) cells during embryonic development. Nurr1 continues to be expressed in adult DA neurons but the role for Nurr1 in inducing and regulating basic dopaminergic functions such as dopamine synthesis and storage has remained unknown. We have previously used MN9D dopamine cells to analyze the role of Nurr1 and retinoids in DA cell maturation. These studies demonstrated that both Nurr1 and retinoids induce cell cycle arrest and a mature morphology. Here we used MN9D cells to investigate how Nurr1 regulates dopaminergic functions. Our results demonstrate that Nurr1, but not retinoids, increases DA content and the expression of aromatic L-amino acid decarboxylase (AADC) and vesicular monoamine transporter-2 (VMAT2) in MN9D cells. In a Nurr1-inducible cell line upregulation of VMAT2 is dependent on continuous Nurr1 expression. Moreover, AADC and VMAT2 are deregulated in midbrain DA cells of Nurr1 knockout embryos as revealed by in situ hybridization. Together, the results provide evidence indicating an instructive role for Nurr1 in controlling DA synthesis and storage.

RACK1 is up-regulated in angiogenesis and human carcinomas

Angiogenesis is crucial for many biological and pathological processes including the ovarian cycle and tumor growth. To identify molecules relevant for angiogenesis, we performed mRNA fingerprinting and subsequent Northern blot analysis using bovine cord‐forming vs. monolayer‐forming endothelial cells (EC) in vitro and staged bovine corpora lutea in vivo. We detected the receptor for activated C kinase 1 (RACK1), the specific receptor for activated protein kinase C β (PKCβ), to be up‐regulated in bovine cord‐forming EC in vitro and in angiogenically active stages of bovine corpora lutea in vivo. Thereafter we established and determined the complete bovine RACK1 cDNA sequence. RACK1 was massively induced in subconfluent vs. contact‐inhibited bovine EC, during angiogenesis in vitro, active phases of the murine ovarian cycle, human tumor angiogenesis, and in cancer cells in vivo as assessed by quantitative PCR and in situ hybridization. RACK1 transcripts were localized to proliferating EC in vitro and the endothelium of tumor neovascularizations in vivo by in situ hybridization. PKCβ plays an important role in angiogenesis and cancer growth. Our data suggest that downstream signaling of PKCβ in angiogenically active vs. inactive tissues and endothelium is affected by the availability of RACK1.—Berns, H., Humar, R., Hengerer, B., Kiefer, F. N., Battegay, E. J. RACK1 is up‐regulated in angiogenesis and human carcinomas. The FASEB J. 14, 2549–2558 (2000)

Differential Regulation of Nerve Growth Factor (NGF) Synthesis in Neurons and Astrocytes by Glucocorticoid Hormones

Glucocorticoid hormones are important regulators of brain development and ageing. Here we show that dexamethasone, a synthetic glucocorticoid, differentially affects the expression of nerve growth factor (NGF) in cultured neurons and astrocytes. Dexamethasone increased the levels of NGF mRNA in cultured hippocampal neurons in a time‐ and concentration‐dependent manner, whereas it down‐regulated the NGF mRNA levels in astrocytes. However, dexamethasone had no effect on the mRNA levels of brain‐derived neurotrophic factor in the hippocampal neurons. Aldosterone, a mineralocorticoid, in higher concentrations also up‐regulated NGF mRNA levels in the hippocampal neurons. Dexamethasone increased the levels of NGF mRNA in the rat hippocampus in vivo, but not to the same extent as observed with kainic acid, a glutamate receptor agonist. There is no apparent diurnal rhythm in the hippocampal NGF protein levels corresponding to circadian variations in the levels of glucocorticoid hormones in serum. The increase in NGF mRNA in the hippocampus in vivo following dexamethasone treatments may reflect the physiological response of hippocampal neurons to high glucocorticoid levels reached under conditions of stress.

The synthesis of nerve growth factor and brain-derived neurotrophic factor in hippocampal and cortical neurons is regulated by specific transmitter systems.

Both nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) exert neurotrophic actions on the cholinergic neurons of the basal forebrain nuclei. These neurotrophic factors are synthesized by hippocampal and cortical neurons that are located in the projection field of the basal forebrain cholinergic neurons. Both in vivo and in vitro the levels of NGF- and BDNF-mRNAs are increased up to 20-fold by kainic acid via non-NMDA glutamate receptors. Enhancement of the effectiveness of the GABAergic system by benzodiazepam or direct GABA agonists blocks the effect of kainic acid and reduces the basic levels of NGF- and BDNF-mRNAs. Whereas the increases in both NGF- and BDNF-mRNAs above normal levels are mediated by non-NMDA receptors, maintenance of the normal levels of NGF- and BDNF-mRNAs seems to be mediated predominantly by NMDA receptors. The regulation of NGF and BDNF synthesis via specific transmitter systems is discussed in the context of the refined tuning of synaptic functions, the potential implications for memory functions, and the possible therapeutic consequences for the treatment of Alzheimers disease.

Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.

In Parkinsons disease (PD) compensatory mechanisms such as an increase of the de novo biosynthesis of dopamine (DA) are thought to delay the onset of motor impairment. Here, we investigated whether the tyrosine hydroxylase (TH) inhibitor alpha-methyl-para-tyrosine (AMPT) affects behavioral deficits in the running wheel activity induced by the selective dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immediately after MPTP treatment C57bl/6 mice showed reduced running wheel activity which lasted during the entire active phase (20:00 to 08:00 h), recovered to baseline levels in the following 2 days and remained stable up to the end of the experiment. AMPT challenge significantly reduced wheel running activity in MPTP-treated mice in the first 3 h after treatment. Post mortem HPLC analysis detected mean striatal DA levels in saline + saline and saline + AMPT-treated mice of 14.32 and 9.83 ng/mg, respectively and in MPTP + saline and MPTP + AMPT-treated mice of 1.73 and 0.69 ng/mg, respectively. Taken together, de novo biosynthesis of DA is a crucial component of the compensatory mechanisms which contributes to masking long-term behavioral deficits in the MPTP mouse model. Additionally, wheel running activity might provide a useful tool to study MPTP-induced behavioral deficits, shifts in circadian rhythmicity, and further compensatory mechanisms relevant to PD.

Pretreatment with aldosterone or corticosterone blocks the memory-enhancing effects of nimodipine, captopril, CGP 37,849, and strychnine in mice.

Oral pretreatment with aldosterone or corticosterone blocked the memory-enhancing effects of the calcium antagonist nimodipine, the ACE inhibitor captopril, the NMDA blocker CGP 37 849, and the glycine antagonist strychnine in a passive-avoidance test in mice. The memory-disturbing effects of phenobarbitone, diazepam, CGP 37 849 and scopolamine were not influenced by the hormonal pretreatment. These findings could indicate the involvement of a steroid-sensitive mechanism in drug-induced improvement of memory. In the light of clinical observations showing elevated cortisol levels in Alzheimer patients, the results might also explain why only a limited number of these patients respond to therapy with memory enhancers.

In Vitro and in Vivo Methods for Evaluating Actions of Cytokines on Nerve Growth Factor Production in Central Nervous System

Publisher Summary This chapter discusses the methods used to study the influence of Interleukin 1 (IL-1) and transforming growth factor β 1 (TGF-β) on nerve growth factor (NGF) production in cultured brain cells and in vivo . It focuses on NGF synthesis. IL-1 plays an important role in many reactions associated with brain injury and reactive gliosis. IL-1 is also present in normal brain and its messenger RNA (mRNA) localizes to neurons, especially in hippocampus. Granule neurons in the dentate gyrus possess IL-1 receptors. IL-1 increases NGF mRNA in the central nervous system in neonatal hippocampus and in cultured rat astrocytes. Transforming growth factor β is a potent cytokine with many diverse actions. It is synthesized by many cells, at least in culture, although in a latent and biologically inactive form. TGF-β elevates NGF mRNA in neonatal rat hippocampus. NGF protein in brain samples or in culture medium is measured by a sensitive two-site enzyme-linked immunosorbent assay (ELISA). The chapter illustrates methods that are used to study the interaction between neurotrophic factors and cytokines.